These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 20672520

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
    Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, Walecki J, Alathiaki AS, Czernikiewicz A.
    Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
    [Abstract] [Full Text] [Related]

  • 3. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
    Szulc A, Galińska B, Tarasów E, Kubas B, Dzienis W, Konarzewska B, Poplawska R, Tomczak AA, Czernikiewicz A, Walecki J.
    Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.
    Strzelecki D, Podgórski M, Kałużyńska O, Gawlik-Kotelnicka O, Stefańczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P.
    Nutrients; 2015 Oct 22; 7(10):8767-82. PubMed ID: 26506383
    [Abstract] [Full Text] [Related]

  • 8. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia.
    Cecil KM, Lenkinski RE, Gur RE, Gur RC.
    Neuropsychopharmacology; 1999 Feb 22; 20(2):131-40. PubMed ID: 9885793
    [Abstract] [Full Text] [Related]

  • 9. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia.
    Jessen F, Scherk H, Träber F, Theyson S, Berning J, Tepest R, Falkai P, Schild HH, Maier W, Wagner M, Block W.
    Schizophr Res; 2006 Oct 22; 87(1-3):81-8. PubMed ID: 16842971
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR Spectroscopy Study.
    Strzelecki D, Grzelak P, Podgórski M, Kałużyńska O, Stefańczyk L, Kotlicka-Antczak M, Gmitrowicz A.
    Int J Mol Sci; 2015 Oct 15; 16(10):24387-402. PubMed ID: 26501256
    [Abstract] [Full Text] [Related]

  • 12. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S, Agoston T, Tamás T, Zoltán J.
    Neuropsychopharmacol Hung; 2007 Oct 15; 9(3):115-24. PubMed ID: 18399029
    [Abstract] [Full Text] [Related]

  • 13. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.
    Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R, Hart B, Lauriello J.
    Neuropsychopharmacology; 2008 Sep 15; 33(10):2456-66. PubMed ID: 18094668
    [Abstract] [Full Text] [Related]

  • 14. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A, Olivares JM, Bousoño M, Gómez JC, Alvarez E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec 30; 30(8):1515-22. PubMed ID: 16820255
    [Abstract] [Full Text] [Related]

  • 15. Proton magnetic resonance spectroscopy changes after antipsychotic treatment.
    Szulc A, Galinska-Skok B, Waszkiewicz N, Bibulowicz D, Konarzewska B, Tarasow E.
    Curr Med Chem; 2013 Dec 30; 20(3):414-27. PubMed ID: 23157634
    [Abstract] [Full Text] [Related]

  • 16. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.
    Kumari V, Antonova E, Geyer MA, Ffytche D, Williams SC, Sharma T.
    Int J Neuropsychopharmacol; 2007 Aug 30; 10(4):463-77. PubMed ID: 16923324
    [Abstract] [Full Text] [Related]

  • 17. [First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings].
    Szulc A.
    Psychiatr Pol; 2007 Aug 30; 41(3):329-38. PubMed ID: 17900049
    [Abstract] [Full Text] [Related]

  • 18. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.
    Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN.
    Psychiatry Res; 1998 Aug 26; 83(2):105-15. PubMed ID: 9818736
    [Abstract] [Full Text] [Related]

  • 19. The predictive value of baseline NAA/Cr for treatment response of first-episode schizophrenia: A ¹H MRS study.
    Liu W, Yu H, Jiang B, Pan B, Yu S, Li H, Zheng L.
    Neurosci Lett; 2015 Jul 23; 600():199-205. PubMed ID: 26099422
    [Abstract] [Full Text] [Related]

  • 20. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA.
    Pharmacopsychiatry; 2009 Mar 23; 42(2):66-71. PubMed ID: 19308881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.